JP2022500455A5 - - Google Patents

Info

Publication number
JP2022500455A5
JP2022500455A5 JP2021514418A JP2021514418A JP2022500455A5 JP 2022500455 A5 JP2022500455 A5 JP 2022500455A5 JP 2021514418 A JP2021514418 A JP 2021514418A JP 2021514418 A JP2021514418 A JP 2021514418A JP 2022500455 A5 JP2022500455 A5 JP 2022500455A5
Authority
JP
Japan
Prior art keywords
composition according
antibody
seq
nlrp3
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514418A
Other languages
English (en)
Japanese (ja)
Other versions
JP7645544B2 (ja
JP2022500455A (ja
Filing date
Publication date
Priority claimed from GBGB1815045.8A external-priority patent/GB201815045D0/en
Application filed filed Critical
Publication of JP2022500455A publication Critical patent/JP2022500455A/ja
Publication of JP2022500455A5 publication Critical patent/JP2022500455A5/ja
Application granted granted Critical
Publication of JP7645544B2 publication Critical patent/JP7645544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514418A 2018-09-14 2019-09-16 Il-1r1およびnlpr3標的化二重特異性抗体 Active JP7645544B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1815045.8 2018-09-14
GBGB1815045.8A GB201815045D0 (en) 2018-09-14 2018-09-14 Bispecific antibody targeting IL-1R1 and NLPR3
PCT/EP2019/074744 WO2020053446A1 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting il-1r1 and nlpr3

Publications (3)

Publication Number Publication Date
JP2022500455A JP2022500455A (ja) 2022-01-04
JP2022500455A5 true JP2022500455A5 (enExample) 2022-09-22
JP7645544B2 JP7645544B2 (ja) 2025-03-14

Family

ID=64013420

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021514418A Active JP7645544B2 (ja) 2018-09-14 2019-09-16 Il-1r1およびnlpr3標的化二重特異性抗体
JP2021514423A Active JP7517702B2 (ja) 2018-09-14 2019-09-16 Il-1r1およびnlpr3標的化二重特異性抗体
JP2024104327A Pending JP2024125385A (ja) 2018-09-14 2024-06-27 Il-1r1およびnlpr3標的化二重特異性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021514423A Active JP7517702B2 (ja) 2018-09-14 2019-09-16 Il-1r1およびnlpr3標的化二重特異性抗体
JP2024104327A Pending JP2024125385A (ja) 2018-09-14 2024-06-27 Il-1r1およびnlpr3標的化二重特異性抗体

Country Status (7)

Country Link
US (2) US12227579B2 (enExample)
EP (3) EP4778533A2 (enExample)
JP (3) JP7645544B2 (enExample)
CN (2) CN112996564A (enExample)
AU (2) AU2019338674B2 (enExample)
GB (1) GB201815045D0 (enExample)
WO (2) WO2020053446A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
EP4268834A4 (en) * 2020-12-28 2024-10-16 MD Healthcare Inc. Composition for preventing or treating eye diseases comprising micrococcus luteus-derived extracellular vesicles
US20250382341A1 (en) * 2022-12-30 2025-12-18 The Regents Of The University Of California Methods and compositions of in vivo engineering of t-cells to anti-inflammatory cells and therapeutic applications there of
CN119950708B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂
CN120535627B (zh) * 2023-06-05 2025-11-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的纯化方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001061005A2 (en) 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2001296333A1 (en) 2000-09-26 2002-04-08 The Burnham Institute Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
WO2007081982A2 (en) 2006-01-10 2007-07-19 The Regents Of The University Of Michigan Methods and compositions for mediation of immune responses and adjuvant activity
FR2937339B1 (fr) 2008-10-21 2013-02-15 Univ Bourgogne Procede de detection de la maladie atheromateuse.
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2011109459A2 (en) 2010-03-04 2011-09-09 University Of Miami Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2013007763A1 (en) 2011-07-12 2013-01-17 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
WO2013113615A1 (en) * 2012-02-03 2013-08-08 F. Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
WO2013119673A1 (en) 2012-02-06 2013-08-15 University Of Miami Innate immune proteins as biomarkers for cns injury
EP2825561A4 (en) 2012-03-15 2016-03-09 Permeon Biolog Inc CELL PENETRATING COMPOSITIONS FOR THE DISPOSAL OF INTRA-CELLULAR ANTIBODIES AND ANTIBODY-RELATED UNITS AND METHODS OF USE
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US20160354437A1 (en) 2014-02-13 2016-12-08 Northwestern University Compositions and methods for modulation of immune response
CN104258398B (zh) * 2014-10-14 2017-12-22 中国科学技术大学 Drd1及其激动剂在制备治疗nlrp3炎症小体相关炎症性疾病药物中的用途
WO2017079352A2 (en) 2015-11-04 2017-05-11 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof
JP2019069905A (ja) * 2016-02-29 2019-05-09 国立大学法人大阪大学 組織損傷治療剤
US20200115358A1 (en) * 2016-03-11 2020-04-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin and icaritin derivatives
US10041044B2 (en) * 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Similar Documents

Publication Publication Date Title
JP2017504578A5 (enExample)
JP7212391B2 (ja) a-syn/IGF1Rに対する二重特異抗体およびその用途
JP2019527553A5 (enExample)
JP2020508655A5 (enExample)
JP2020534830A5 (enExample)
JP2021502984A5 (enExample)
JP2018517431A5 (enExample)
JP2018516853A5 (enExample)
JP2018522888A5 (enExample)
JP2013091655A5 (enExample)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
RU2013115927A (ru) АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
RU2019134462A (ru) Антитела, связывающиеся с steap-1
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
RU2016100892A (ru) Антитела против tweakr и их применение
RU2010132956A (ru) Ангиопоэтин-2-специфические связывающие агенты
JP2019507580A5 (enExample)
JP2020515277A5 (enExample)
JP2019505166A5 (enExample)
RU2018102803A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2021511387A5 (enExample)
KR102754842B1 (ko) 신규 항 hsa 항체
JP2019504615A5 (enExample)
JP2023511898A5 (enExample)
JP2024515560A5 (enExample)